SEC Tracker
Get the app

X4 Pharmaceuticals XFOR

X4 Pharmaceuticals reports stock option grant to David Kirske

David Kirske (CFO) reported option or other derivative trades in XFOR

Form
4
Filed
Importance
Routine
  1. Stock options for 1,552,769 shares granted on Oct 29, 2025
  2. Options vest over 24 months starting Aug 12, 2026
  3. Performance condition met on Oct 29, 2025

Written from the Form 4 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when X4 Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Akari Therapeutics AKTX public float $15M, Jun 30, 2025
  2. ProPhase Labs PRPH public float $15M, Jun 30, 2025
  3. Pluri PLUR public float $15M, Dec 31, 2025
  4. CalciMedica CALC public float $16M, Jun 30, 2025
  5. Edesa Biotech EDSA public float $14M, Mar 31, 2025, over 18 months old

Data on this page was fetched . The filing on SEC.gov is the record.